-
Alumis NasdaqGS:ALMS Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Location: 280 East Grand Avenue, South San Francisco, CA, 94080, United States | Website: https://www.alumis.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
35.86M
Cash
208.7M
Avg Qtr Burn
-72.79M
Short % of Float
53.50%
Insider Ownership
0.63%
Institutional Own.
53.97%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ESK-001 Details Moderate-to-severe plaque psoriasis | Phase 3 Data readout | |
ESK-001 Details Systemic lupus erythematosus | Phase 2b Data readout | |
A-005 Details Multiple sclerosis | Phase 2 Initiation |